Therapeutics for cancer are entering a new era, where precision approaches promise to revolutionize the way in this disease is treated. This comprehensive course reviews current and emerging drugs, immunotherapies, their application to specific cancer types, how to conduct clinical trials for oncologic therapies, and the drug development process for drug candidates leading to their approval. The US Food & and Drug Administration (FDA) regulatory considerations for Oncology drugs, registration endpoints, and accelerated and Breakthrough approval mechanisms are also covered.
Benefits of Attendance
Download the final course agenda for PERI’s comprehensive Cancer program.
Continuing Education Credit
Pharmaceutical Education & Research Institute, Inc. (PERI) is pleased to make continuing education credit available to you for attendance at this program. To receive credit, you must attend the entire program and submit the Continuing Education Application form directly to a PERI on-site coordinator. Additional $35 fee applies for students who are applying for continuing education credit.
Pharmaceutical Education & Research Institute, Inc. (PERI) is accredited by the Accreditation Council for Pharmacy Education as a provider f continuing pharmacy education. ACPE Universal Activity Number is 0708-0000-17-005-L01-P. 1.95 continuing education units (CEUs) are available for this program. Initial Release Date: 10/25/17. This is a knowledge based CPE Activity.
PERI, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. PERI, Inc. designates this live activity for a maximum of 19.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Date: October 25-27, 2017
Location: One Washington Circle Hotel, Washington, DC 20037
Course Price: $1995
Early Bird Pricing: $1795
This course has concluded. Visit our course calendar to view upcoming scheduled programs.
Request a Proposal
Interested in bringing this course to your company? Request a proposal and a PERI team member will be in touch about hosting this course as a Corporate Education program.
1 “I have a better understanding of disease states and treatment options to draw from when planning clinical trials.”
2 “I have a better appreciation of the bleakness of certain cancers for patient outcomes and the urgent need for development of effective treatments.”
3 “I will now try to focus clinical terms on designing studies that are more focused on specific patient populations.”